Loading…
Loading…
As of 20 Nov 2026: Natco Pharma ₹814.30 (m-cap ₹15,960 Cr, P/E 17.8) vs NEULANDLAB ₹20,642.00 (m-cap ₹26,422 Cr, P/E 58.5). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | Natco Pharma | NEULANDLAB |
|---|---|---|
| Share price | ₹814.30 | ₹20,642.00 |
| Day change | −0.93% | −2.18% |
| Market cap | ₹15,960 Cr | ₹26,422 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | 17.8 | 58.5 |
| P/BPrice ÷ book value per share. | 1.5 | 13.1 |
| ROEReturn on equity. | 17.1% | 21.2% |
| ROCEReturn on capital employed. | 17.0% | 26.0% |
| Sales growth (3Y CAGR) | 14.6% | 19.3% |
| Profit growth (3Y CAGR) | 27.0% | 30.0% |
| Debt to equity | 0.11 | 0.17 |
| Dividend yield | 0.52% | 0.16% |
| 1-year price return | −4.8% | +23.5% |
| Promoter holding | 46.2% | 32.3% |
| Industry | Pharmaceuticals | Pharmaceuticals |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Neuland Laboratories Ltd is larger, with a market cap of ₹26,422 Cr against ₹15,960 Cr for Natco Pharma Ltd as of 20 Nov 2026 — about 1.7 times the size.
Natco Pharma Ltd trades at a P/E of 17.8 against 58.5 for Neuland Laboratories Ltd as of 20 Nov 2026. A lower P/E alone does not make a share cheaper in value terms: growth, return on capital and debt differ between companies.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours and ratios update when the companies report results. Each number is the same one shown on the two stock pages.